Minerva Neurosciences, Inc (NERV) financial statements (2021 and earlier)
Company profile
| Business Address |
1601 TRAPELO ROAD WALTHAM, MA 02451 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 46 | 88 | 128 | 83 | 32 | 19 | ||
| Cash and cash equivalents | 21 | 50 | 26 | 83 | 14 | 19 | ||
| Short-term investments | 24 | 38 | 102 | 18 | ||||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Prepaid expense | 1 | 2 | 1 | 1 | 1 | 1 | ||
| Total current assets: | 47 | 90 | 130 | 84 | 33 | 19 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Long-term investments and receivables | 5 | |||||||
| Long-term investments | 5 | |||||||
| Intangible assets, net (including goodwill) | 30 | 49 | 49 | 49 | 49 | 49 | ||
| Goodwill | 15 | 15 | 15 | 15 | 15 | 15 | ||
| Intangible assets, net (excluding goodwill) | 15 | 34 | 34 | 34 | 34 | 34 | ||
| Other noncurrent assets | 0 | 0 | 0 | |||||
| Total noncurrent assets: | 30 | 49 | 54 | 49 | 49 | 49 | ||
| TOTAL ASSETS: | 77 | 139 | 184 | 133 | 83 | 68 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 3 | 2 | 2 | 2 | 2 | 2 | ||
| Accounts payable | 2 | 2 | 1 | 1 | 1 | 1 | ||
| Accrued liabilities | 0 | 0 | 0 | 0 | 1 | |||
| Employee-related liabilities | 0 | 1 | 1 | |||||
| Taxes payable | 0 | |||||||
| Interest and dividends payable | 0 | 0 | 0 | |||||
| Other undisclosed accounts payable and accrued liabilities | (1) | |||||||
| Debt | 0 | 4 | 5 | 1 | 1 | |||
| Deferred revenue and credits | ✕ | ✕ | 0 | |||||
| Other undisclosed current liabilities | 4 | 1 | 1 | 3 | 2 | 0 | ||
| Total current liabilities: | 7 | 4 | 7 | 10 | 5 | 4 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 0 | 4 | 9 | |||||
| Long-term debt, excluding current maturities | 4 | 9 | ||||||
| Operating lease, liability | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 43 | 41 | 45 | 13 | 13 | 13 | ||
| Deferred revenue and credits | ✕ | ✕ | 41 | |||||
| Deferred revenue | 41 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Contract with customer, liability | ✕ | 41 | ✕ | ✕ | ✕ | ✕ | ||
| Deferred tax liabilities, net | ✕ | 4 | 13 | 13 | 13 | |||
| Deferred income tax liabilities | 2 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Other liabilities | 0 | 0 | 0 | |||||
| Other undisclosed noncurrent liabilities | 4 | |||||||
| Total noncurrent liabilities: | 43 | 45 | 45 | 17 | 22 | 13 | ||
| Total liabilities: | 50 | 49 | 52 | 27 | 27 | 17 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 28 | 90 | 132 | 106 | 55 | 51 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 315 | 305 | 296 | 239 | 157 | 126 | ||
| Accumulated deficit | (287) | (215) | (164) | (133) | (102) | (75) | ||
| Total stockholders' equity: | 28 | 90 | 132 | 106 | 55 | 51 | ||
| TOTAL LIABILITIES AND EQUITY: | 77 | 139 | 184 | 133 | 83 | 68 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (76) | (52) | (41) | (30) | (26) | (55) | |
| Operating loss: | (76) | (52) | (41) | (30) | (26) | (55) | |
| Nonoperating income | 1 | 2 | 1 | 0 | 0 | 0 | |
| Investment income, nonoperating | 1 | 2 | 1 | 0 | 0 | ||
| Foreign currency transaction gain (loss), before tax | (0) | (0) | (0) | (0) | (0) | 0 | |
| Loss from continuing operations before equity method investments, income taxes: | (74) | (50) | (40) | (30) | (26) | (55) | |
| Other undisclosed loss from continuing operations before income taxes | (0) | (1) | |||||
| Loss from continuing operations before income taxes: | (74) | (50) | (41) | (30) | (26) | (55) | |
| Income tax benefit | 2 | 9 | |||||
| Net loss: | (72) | (50) | (32) | (30) | (26) | (55) | |
| Other undisclosed net loss attributable to parent | (1) | (1) | |||||
| Net loss attributable to parent: | (72) | (50) | (32) | (31) | (27) | (55) | |
| Other undisclosed net loss available to common stockholders, basic | (2) | ||||||
| Net loss available to common stockholders, diluted: | (72) | (50) | (32) | (31) | (27) | (57) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (72) | (50) | (32) | (30) | (26) | (55) | |
| Comprehensive loss, net of tax, attributable to parent: | (72) | (50) | (32) | (30) | (26) | (55) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.